Alzheimer’s disease is the most common neurodegenerative disease with over 50 million people affected worldwide, and with an aging population this is set to triple by 2050. With very limited curative treatments available, and many failed clinical trials seen historically, the need for well-designed trials and effective clinical testing is crucial for the development of new treatments to prevent, halt or cure Alzheimer’s Disease.

Julius clinical provides three key success criteria for conducting Alzheimer’s Disease clinical trials;

1. Scientific excellence through our close working relationship with Prof. Scheltens, the academic Key Opinion Leader in the Alzheimer’s Disease field
2. Operational in-house expertise and a track record in running Alzheimer’s Disease clinical trials
3. Partnership with site networks and key research centers including Amsterdam Neuroscience and the Brain Research Center in The Netherlands